Investment Rating - The report does not explicitly state an investment rating for the company Core Insights - The company is a leader in the high-end domestic skincare market in China, focusing on anti-wrinkle and firming skincare products, with its flagship brand "Lin Qing Xuan" offering high-end skincare solutions based on natural camellia ingredients [3][8] - The market for skincare products in China is projected to reach CNY 688.6 billion by 2024, with a compound annual growth rate (CAGR) of 6.8% from 2019 to 2024, and an expected CAGR of 8.6% from 2024 to 2029 [4][37] - The facial essence oil category, driven by the "oil-based skincare" trend, is expected to grow significantly, with a market size of CNY 5.3 billion in 2024 and a CAGR of 42.8% from 2019 to 2024 [4][37] - The company has seen substantial revenue growth, with a projected revenue of CNY 1.21 billion in 2024, representing a 50.3% year-on-year increase [18] Company Overview - The company has established itself as a rare high-end domestic skincare brand, with its camellia essence oil being the top-selling product in the facial essence oil category for 11 consecutive years [3][8] - The company has a balanced distribution of online and offline channels, with online sales growing significantly, contributing to overall revenue growth [5][25] - The company has a strong presence in the high-end anti-wrinkle skincare market, ranking first among domestic brands and being the only domestic brand in the top ten [3][8] Market Trends - The demand for anti-wrinkle and firming skincare products is high, with a projected market size of CNY 119.8 billion in 2024 and a CAGR of 15.0% from 2019 to 2024 [49] - The high-end skincare segment is expected to grow faster than the mass market, with a projected CAGR of 8.9% from 2019 to 2024 [43] Financial Performance - The company's gross margin has been consistently high, with projections of 82.5% in 2024, and a significant improvement in net profit margin from -0.9% in 2022 to 15.4% in 2024 [88] - The company has achieved a turnaround in profitability, with a net profit of CNY 187 million in 2024, representing a 121.1% year-on-year increase [18][88] Distribution Channels - The company has expanded its offline presence, with a total of 506 stores by the end of 2024, primarily located in shopping malls [78] - Online sales have become the dominant revenue source, accounting for 59.1% of total revenue in 2024, with significant growth in both direct sales and sales through online retailers [25][74] Product Strategy - The company's primary product category is facial essence oil, which has seen a revenue increase from CNY 218 million in 2022 to CNY 448 million in 2024, with a growing market share [66][70] - The company has successfully positioned its camellia essence oil as a leading product in the market, with cumulative sales exceeding 30 million bottles by the end of 2024 [66]
贝康医疗-B（02170）：招股说明书解读：以小见大、以油养肤，塑造高端护肤品牌心智